Improve Medical Instruments Co (300030) Fair Value & Analysis
Healthcare · CN · Market cap 2.0B CNY
Fair value as of: Jun 24, 2026
Analysis
Improve Medical Instruments Co (300030) currently trades at ¥6.29, while our model-based Fair Value estimate is ¥1.47 — implying the stock looks roughly 76.6% overvalued today. We read business quality at 90/100 (high quality), in the Healthcare sector. Bear case: priced above our estimate, the market already discounts strong expectations. Bull case: above-average quality can justify a premium — the entry price still matters most (evidence: high).
About the company
Improve Medical Instruments Co., Ltd. engages in the provision of relevant technologies, products, and services for clinical laboratory and clinical nursing in China and internationally. It provides clinical laboratory products comprising feces and thrombosis viscoelastic analysis systems; and automatic biosafety decappers; and Q-VELOX, an intelligent molecular diagnostic workstation. The company also offers offers specimen processing equipment, including evacuated blood collection systems, evacuated blood collection tubes, multi-sample needles, blood collection sets, tourniquets and disposable tourniquets, urine collection systems, and holders under IMPROVACUTER brand name; and IMPROMINI capillary blood collection systems, IMPROSWAB microbiological transportation systems, IMPRONURSE infusion pumps and syringe pumps, LONGX urine analysis systems, in-vitro diagnostic reagents, IMPROSAFE safety blood collection needles, IMPROVE sharps containers, liquid biopsy pre-analytical systems, …
Open the full interactive analysis →
Similar stocks
Frequently asked questions
Is Improve Medical Instruments Co (300030) undervalued?
What is the fair value of 300030?
What is the quality score of 300030?
How we calculate Fair Value
Each company is valued through a stack of independent intrinsic-value models (DCF variants, residual-income, multiples and more), blended into one family-balanced consensus and weighted by how much trustworthy data backs it. A separate quality layer scores the fundamentals. Every input is real reported data — nothing guessed.
Educational research only · not financial advice · no buy/sell recommendation. Model-based estimates are not certainties; their reliability depends on data quality and assumptions.